Abstract
The glycine receptor (GlyR) Cl- channel belongs to the cysteine-loop family of ligand-gated ion channel receptors. It is best known for mediating inhibitory neurotransmission in motor and sensory reflex circuits of the spinal cord, although glycinergic synapses are also present in the brain stem, cerebellum and retina. Extrasynaptic GlyRs are widely distributed throughout the central nervous system and they are also found in sperm and macrophages. A total of 5 GlyR subunits (α1-4 and β) have been identified. Embryonic receptors comprise α2 homomers whereas adult receptors comprise predominantly α1β heteromers in a 2:3 stoichiometry. Notably, the α3 subunit is present in synaptic GlyRs that mediate inhibitory neurotransmission onto spinal nociceptive neurons. These receptors are specifically inhibited by inflammatory mediators, implying a role for α3-containing GlyRs in inflammatory pain sensitisation. Because molecules that increase GlyR current may have clinical potential as muscle relaxant and peripheral analgesic drugs, this review focuses on the molecular pharmacology of GlyR potentiating substances. Of all GlyR potentiating substances identified to date, we conclude that 5HT3R antagonists such as tropisetron offer the most promise as therapeutic lead compounds. However, one problem is that that virtually all known GlyR potentiating compounds, including tropisetron analogues, lack specificity for the GlyR. Another is that almost nothing is known about the pharmacological properties of α3-containing GlyRs, which is the subtype of choice for targeting by novel antinociceptive agents. These issues need to be addressed before GlyR-specific therapeutics can be developed.
Keywords: Inhibitory neurotransmission, inflammatory pain, startle disease, hyperekplexia, glycinergic, cysteine-loop receptor family, therapeutic target
Current Pharmaceutical Design
Title: Molecular Pharmacology of the Glycine Receptor Chloride Channel
Volume: 13 Issue: 23
Author(s): Timothy I. Webb and Joseph W. Lynch
Affiliation:
Keywords: Inhibitory neurotransmission, inflammatory pain, startle disease, hyperekplexia, glycinergic, cysteine-loop receptor family, therapeutic target
Abstract: The glycine receptor (GlyR) Cl- channel belongs to the cysteine-loop family of ligand-gated ion channel receptors. It is best known for mediating inhibitory neurotransmission in motor and sensory reflex circuits of the spinal cord, although glycinergic synapses are also present in the brain stem, cerebellum and retina. Extrasynaptic GlyRs are widely distributed throughout the central nervous system and they are also found in sperm and macrophages. A total of 5 GlyR subunits (α1-4 and β) have been identified. Embryonic receptors comprise α2 homomers whereas adult receptors comprise predominantly α1β heteromers in a 2:3 stoichiometry. Notably, the α3 subunit is present in synaptic GlyRs that mediate inhibitory neurotransmission onto spinal nociceptive neurons. These receptors are specifically inhibited by inflammatory mediators, implying a role for α3-containing GlyRs in inflammatory pain sensitisation. Because molecules that increase GlyR current may have clinical potential as muscle relaxant and peripheral analgesic drugs, this review focuses on the molecular pharmacology of GlyR potentiating substances. Of all GlyR potentiating substances identified to date, we conclude that 5HT3R antagonists such as tropisetron offer the most promise as therapeutic lead compounds. However, one problem is that that virtually all known GlyR potentiating compounds, including tropisetron analogues, lack specificity for the GlyR. Another is that almost nothing is known about the pharmacological properties of α3-containing GlyRs, which is the subtype of choice for targeting by novel antinociceptive agents. These issues need to be addressed before GlyR-specific therapeutics can be developed.
Export Options
About this article
Cite this article as:
Timothy I. Webb and Joseph W. Lynch , Molecular Pharmacology of the Glycine Receptor Chloride Channel, Current Pharmaceutical Design 2007; 13 (23) . https://dx.doi.org/10.2174/138161207781368693
DOI https://dx.doi.org/10.2174/138161207781368693 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phenolic Acids Exert Anticholinesterase and Cognition-Improving Effects
Current Alzheimer Research Prevention of Contrast Induced Nephropathy
Current Drug Therapy Exosomal MicroRNA: Diagnostic Marker and Therapeutic Tool for Lung Diseases
Current Pharmaceutical Design Women’s Ginseng (Angelica sinensis): An Ethnopharmacological Dossier
Current Traditional Medicine Recent Advances in Ethnopharmacological and Toxicological Properties of Bioactive Compounds from <i>Aloe barbadensis</i> (Miller), <i>Aloe vera</i>
Current Bioactive Compounds Cardiac Toxicity of Antineoplastic Anthracyclines
Current Medicinal Chemistry - Anti-Cancer Agents MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design Protein Kinase C Pharmacology: Perspectives on Therapeutic Potentials as Antidementic and Cognitive Agents
Recent Patents on CNS Drug Discovery (Discontinued) The Cardioprotective Peptide, Urocortin, Activates Cardiac KATP Channels in Adult Rat.
Protein & Peptide Letters The Neuropeptide Systems and their Potential Role in the Treatment of Mammalian Retinal Ischemia: A Developing Story
Current Neuropharmacology Therapeutic Hypothermia for Cardiopulmonary Resuscitation: Why, When and How
Current Cardiology Reviews Brown Recluse Spider Venom: Proteomic Analysis and Proposal of a Putative Mechanism of Action
Protein & Peptide Letters Anti-Angiogenic Effects of Resveratrol on Cerebral Angiogenesis
Current Neurovascular Research Antioxidant Effect of Flavonoids Present in Euterpe oleracea Martius and Neurodegenerative Diseases: A Literature Review
Central Nervous System Agents in Medicinal Chemistry Conantokins: Peptide Antagonists of NMDA Receptors
Current Medicinal Chemistry The Role of Dietary Polyphenols in the Management of Inflammatory Bowel Disease
Current Pharmaceutical Biotechnology Chemokine Contribution in Stem Cell Engraftment into the Infarcted Myocardium
Current Stem Cell Research & Therapy Commentary (Research Highlights: Targeted Inhibition of miR-155 Promotes Post-Stroke Neovascularization and Functional Recovery)
CNS & Neurological Disorders - Drug Targets Anesthetic Pharmacology for Kidney Transplantation
Current Clinical Pharmacology Metabolism and Pharmacological Mechanisms of Active Ingredients in <i>Erigeron breviscapus</i>
Current Drug Metabolism